An Open Label Phase II Biomarker Study of Nivolumab the anti-PD-1 antibody in Japanese Subjects with pretreated non-small cell lung cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 02 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Nov 2015 New trial record